Hospital/Health-System Pharmacy

Will price impede recently approved implant for opioid addicts?Probuphine implant could be a new option for addicts if obstacles, such as price, don’t get in the way.
Proposed Medicare Part B rule would cut payments for some drugsNew analysis finds proposed Medicare payment changes for physician-administered drugs would reduce reimbursement for those that cost more than $480 per day in 2016. Seven of the 10 drugs that constitute the largest reduction in reimbursement are used to treat cancer.
Shaping specialty pharmacy’s future: 4 perspectivesAt AMCP, four stakeholders representing the specialty pharmacy perspective, manufacturer perspective, payer perspective, and PBM perspective shared their thoughts on the future of specialty pharmacy.

AMCP Annual Meeting highlights specialty pharmaceutical challengesThe CEO of the Academy of Managed Care Pharmacy identifies key challenges and opportunities that will be discussed at the annual meeting.
Benzos linked to adverse health eventsThe death rate from overdoses involving benzodiazepines, a class of sedatives that includes Xanax, Valium, and Klonopin, has increased more than four-fold since 1996, according to a study appearing online in the American Journal of Public Health.
Brand-name patent losses raise pharma cost concernsA number of traditional brand-name pharmaceuticals have lost, or will lose, patent protection this year. What does this mean over the longer-term for controlling costs?

Three ways to get the most mileage from mobile appsNew research: Hospitals risk millions from failure to provide consumer-friendly mobile apps. How to achieve exceptional consumer experience.
New rheumatoid arthritis therapies are comingFour new drugs and a biosimilar should be on your radar.
New data: Treating injection drug users with HCVNew study results show that people with chronic HCV who inject drugs and are on opioid agonist therapy respond well to an investigational therapy.
Antidepressant drug coverage may require special handlingA new Urban Institute study looks at the availability of antidepressants in marketplace insurance plans.